Vistin Pharma ASA (LTS:0RAM) Additional Paid-In Capital: kr73.9 Mil(As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
71 GF Score
Price kr20.00
GF Value kr25.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Additional Paid-In Capital?

Vistin Pharma ASA LTS:0RAM 71 Additional Paid-In Capital is kr73.9 Mil as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 71/100 and a GF Value™ of kr25.97 (Modestly Undervalued). The stock has 3 warning signs investors should review.


Vistin Pharma ASA's quarterly additional paid-in capital stayed the same from Sep. 2025 (kr73.9 Mil) to Dec. 2025 (kr73.9 Mil) and stayed the same from Dec. 2025 (kr73.9 Mil) to Mar. 2026 (kr73.9 Mil).

Vistin Pharma ASA's annual additional paid-in capital declined from Dec. 2023 (kr206.9 Mil) to Dec. 2024 (kr129.3 Mil) and declined from Dec. 2024 (kr129.3 Mil) to Dec. 2025 (kr73.9 Mil).

Vistin Pharma ASA Additional Paid-In Capital Related Terms

Vistin Pharma ASA Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Additional Paid-In Capital Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 206.89 206.89 206.89 129.30 73.87

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.30 73.87 73.87 73.87 73.87
LTS:0RAM
71GF Score
Vistin Pharma ASA LTS:0RAM
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of kr73.9 Mil mean?
Vistin Pharma ASA (LTS:0RAM) has a Additional Paid-In Capital of kr73.9 Mil as of Mar. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Additional Paid-In Capital too high?
Vistin Pharma ASA's current Additional Paid-In Capital is kr73.9 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Additional Paid-In Capital compare to ZTS and UTHR?
Vistin Pharma ASA's Additional Paid-In Capital of kr73.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Additional Paid-In Capital is kr73.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.97, compared to a current price of kr20.00 — trading 23% below its estimated fair value. The current Additional Paid-In Capital is kr73.9 Mil. Vistin Pharma ASA's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Additional Paid-In Capital is kr73.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.00 is trading 23% below its estimated GF Value™ of kr25.97. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Additional Paid-In Capital: kr73.9 Mil
  • GF Value™: kr25.97 vs. price of kr20.00 (23% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
71GF Score

Get the complete analysis for LTS:0RAM

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.00
Price
kr25.97
GF Value